drugset / Trial / NCT02236806

Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

NCT02236806

RandomizedParallel-groupDouble-blindPrevention

Summary

The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.

Timeline

Start
2015-07
Primary completion
2022-06
Completion
2022-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bisoprolol Other / unclassified 5 mg
Subject Ramipril Small molecule 5 mg